39th week of 2011 patent applcation highlights part 44 |
Patent application number | Title | Published |
20110236277 | MICROFLUID CONTROL DEVICE AND METHOD OF MANUFACTURING THE SAME - Provided are a plastic microfluid control device having a multi-step microchannel and a method of manufacturing the same. The device includes a lower substrate, and a fluid channel substrate contacting the lower substrate and having a multi-step microchannel having at least two depths in a side coupling to the lower substrate. Thus, the device can precisely control the fluid flow by controlling capillary force in a depth direction of the channel by controlling the fluid using the multi-step microchannel having various channel depths. A multi-step micropattern is formed by repeating photolithography and transferred, thereby easily forming the multi-step microchannel having an even surface and a precisely controlled height. | 2011-09-29 |
20110236278 | PIPETTE TIP TRAYS - Provided are pipette tip trays for use in biotechnology applications. In certain embodiments, provided are pipette tip trays having one or more of the following features: (i) lacking an external hinge between the lid and the rack, and (ii) having snap plate fasteners configured to releasably secure a snap plate to a base. | 2011-09-29 |
20110236279 | INTEGRATED REACTORS, METHODS OF MAKING SAME, AND METHODS OF CONDUCTING SIMULTANEOUS EXOTHERMIC AND ENDOTHERMIC REACTIONS - Integrated Combustion Reactors (ICRs) and methods of making ICRs are described in which combustion chambers (or channels) are in direct thermal contact to reaction chambers for an endothermic reaction. Superior results were achieved for combustion chambers which contained a gap for free flow through the chamber. Particular reactor designs are also described. Processes of conducting reactions in integrated combustion reactors are described and results presented. Some of these processes are characterized by unexpected and superior results. | 2011-09-29 |
20110236280 | METHOD FOR PURIFYING EXHAUST GAS AND SYSTEM THEREFORE - A method is provided for purifying exhaust gas from an engine having an exhaust passage with a selective reducing catalyst and an oxidation catalyst upstream of the selective reducing catalyst. The method calculates an amount of NOx that flows into the selective reducing catalyst; sets an amount of an additive agent to be supplied to the selective reducing catalyst based on the calculated amount of NOx; determines a degradation degree of the oxidation catalyst; determines whether a correction to the amount of the additive agent is necessary based on the determined degradation degree of the oxidation catalyst; corrects the amount of the additive agent to be supplied when the correction is necessary; and supplies the additive agent to the selective reducing catalyst in the corrected amount if the amount is determined to be corrected and in the uncorrected amount if the amount is determined not to be corrected. | 2011-09-29 |
20110236281 | METHOD FOR REMOVAL OF HYDROGEN SULFIDE FROM GEOTHERMAL STEAM AND CONDENSATE - A method for scavenging hydrogen sulfide from geothermal steam in a condenser under vacuum. A fine curtain of atomized acrolein-water droplets may be sprayed into geothermal steam condensers in an amount of approximately 2:1 molar ratio of acrolein to H | 2011-09-29 |
20110236282 | ZROX, CE-ZROX, CE-ZR-REOX AS HOST MATRICES FOR REDOX ACTIVE CATIONS FOR LOW TEMPERATURE, HYDROTHERMALLY DURABLE AND POISON RESISTANT SCR CATALYSTS - The present invention relates to application of catalysts for the Selective Catalytic Reduction of oxides of Nitrogen using N-containing reductant. The catalysts are characterised as phase pure lattice oxide materials into which catalytically active cations are incorporated at high levels of dispersion such that conventional analysis reveals a highly phase pure material. The materials are further characterised by high activity, hydrothermal durability and poison tolerance in the intended application. | 2011-09-29 |
20110236283 | NOx REMOVAL CATALYST FOR HIGH-TEMPERATURE FLUE GAS, MANUFACTURING METHOD THEREOF, AND NOx REMOVAL METHOD FOR HIGH-TEMPERATURE FLUE GAS - A NOx removal catalyst for high-temperature flue gas according to the present invention is a NOx removal catalyst for high-temperature flue gas that contains nitrogen oxide in which tungsten oxide with the number of molecular layers of tungsten oxide (WO | 2011-09-29 |
20110236284 | PHOTOCATALYST-COATED BODY AND PHOTOCATALYTIC COATING LIQUID - Disclosed are a photocatalyst-coated body that can realize a good weather resistance, a photocatalyst-coated body that, in removing NOx, particularly in removing NOx in air, can suppress the production of an intermediate product such as NO | 2011-09-29 |
20110236285 | METHOD FOR PRODUCING METAL HYDROXIDE FINE PARTICLE - An object of the present invention is to provide a method for producing a metal hydroxide fine particle, which can produce metal hydroxide fine particles with favorable crystallinity and small particle sizes. The present invention provides a method for producing a metal hydroxide fine particle by reacting a metal ion with a hydroxide ion in a solvent, which includes a mixing and reacting step of supplying the metal ion, the hydroxide ion, and a silane coupling agent to a reaction field to mix and react the ions. | 2011-09-29 |
20110236286 | PROCESS FOR PRODUCTION OF A BOROHYDRIDE COMPOUND - A process for production of a borohydride compound M(BH | 2011-09-29 |
20110236287 | PROCESS FOR PRODUCTION OF AN ALUMINUM HYDRIDE COMPOUND - A compound of formula M(AlH | 2011-09-29 |
20110236288 | METHOD FOR PRODUCING HIGH-PURITY SIO2 FROM SILICATE SOLUTIONS - The invention relates to a novel method for producing high-purity SiO | 2011-09-29 |
20110236289 | CHLOROSILANE PRODUCTION METHOD - When a disproportionated chlorosilane is to be produced by causing a starting material chlorosilane liquid to flow through a catalyst-packed layer which is packed with a weakly basic anion exchange resin as a disproportionation reaction catalyst to carry out a disproportionation reaction, before the disproportionation reaction is carried out, the disproportionation reaction catalyst is brought into contact with a processing gas obtained by diluting a chlorosilane with an inert gas to prevent the deterioration of the disproportionation reaction catalyst at the start of the reaction so as to carry out the disproportionation of the chlorosilane efficiently. | 2011-09-29 |
20110236290 | METHOD FOR PROCESSING SILICON POWDER TO OBTAIN SILICON CRYSTALS - Embodiments of the present invention relate to a process for obtaining silicon crystals from silicon. The method includes contacting silicon powder with a solvent metal to provide a mixture containing silicon, melting the silicon under submersion to provide a first molten liquid, contacting the first molten liquid with a first gas to provide dross and a second molten liquid, separating the dross and the second molten liquid, cooling the second molten liquid to form first silicon crystals and a first mother liquid and separating the first silicon crystals and the first mother liquid. | 2011-09-29 |
20110236291 | SYSTEM FOR PRODUCING SILICON WITH IMPROVED RESOURCE UTILIZATION - The present invention relates to a system for producing silicon, preferably high-purity silicon, particularly solar silicon, and to a method for producing silicon, preferably high-purity silicon, in particular solar silicon, in each case with particularly effective resource utilization and reduced emission of pollutants. | 2011-09-29 |
20110236292 | Clean bench and method of producing raw material for single crystal silicon - A clean bench comprising a worktable on which polycrystalline silicon is placed, a box part which includes side plates to surround three sides except a front face of a working space above the worktable, and a ceiling plate which covers an upper side of the working space. Supplying holes are formed in the ceiling plate of the box part, which supply clean air onto an upper surface of the worktable. An ionizer is provided, which ionizes the clean air supplied from the supplying holes to the working space and removes static electricity on the worktable. Suction holes are formed in the side plate of the box part, which suction air from the working space. | 2011-09-29 |
20110236293 | INTEGRATED GAS REFINERY - The present invention relates to an integrated synthesis gas refinery plant and a process for the simultaneous production from a single synthesis gas stream X of a hydrogen stream useful for the production of ammonia, a hydrogen rich synthesis gas stream useful for the production of methanol, and a hydrogen depleted synthesis gas stream useful for the production of hydrocarbons. | 2011-09-29 |
20110236294 | Saturation of Ammonia Storage Materials in Containers - A method of saturating reversible ammonia storage materials inside a container for the purpose of achieving high volumetric ammonia storage capacity and containers filled with the materials are disclosed. | 2011-09-29 |
20110236295 | Polymeric Ionic Liquids, Methods of Making and Methods of Use Thereof - Polymeric ionic liquids, methods of making and methods of using the same are disclosed. | 2011-09-29 |
20110236296 | METHOD OF PURIFYING HYDROCHLORIC ACID - Provided is a method of purifying hydrochloric acid by removing an organic substance having a boiling point of −25° C. to 120° C. under atmospheric pressure from an organic substance-containing hydrochloric acid that contains the organic substance and has a hydrogen chloride concentration higher than an azeotropic hydrogen chloride concentration under atmospheric pressure. The method includes the step of subjecting the organic substance-containing hydrochloric acid to distillation using a distillation tower at an operation pressure set such that an azeotropic hydrogen chloride concentration under the operation pressure is higher than the hydrogen chloride concentration of the organic substance-containing hydrochloric acid, to distill out the organic substance from the top of the distillation tower. | 2011-09-29 |
20110236297 | HEAT TREATMENT METHOD OF ZNTE SINGLE CRYSTAL SUBSTRATE AND ZNTE SINGLE CRYSTAL SUBSTRATE - The present invention is to provide a heat treatment method for effectively eliminating Te deposits in a ZnTe single crystal substrate, and a ZnTe single crystal substrate having an optical characteristic suitable for use of a light modulation element and having a thickness of 1 mm or more. A heat treatment method of a ZnTe single crystal substrate, includes: a first step of increasing a temperature the ZnTe single crystal substrate to a first heat treatment temperature T | 2011-09-29 |
20110236298 | Adsorbent for Water Adsorption and Desorption - The present invention relates to methods for absorbing and/or desorbing water by contacting water with hybrid inorganic-organic material having high surface area, and pores with the size of molecules or nanometers. More specifically, the water adsorbent has facile adsorption-desorption even below 100° C., having high adsorption capacity, and having high desorption capacity when it is heated up to the temperature below 100° C. The adsorbent of the present invention can be applied to a humidifier, dehumidifier, cooler and heater. The present invention also relates to a technology to control humidity using the adsorbent. | 2011-09-29 |
20110236299 | METHOD FOR MAKING LITHIUM-ION BATTERY ELECTRODE MATERIAL - The present disclosure relates to a method for making an electrode material of lithium-ion batteries. In the method, a lithium source solution and a plurality of titanium source particles are provided. The lithium source solution and the titanium source particles are mixed, wherein a molar ratio of lithium element to titanium element is in a range from about 4:5 to about 9:10, thereby forming a sol. A carbon source compound is dispersed into the sol to form a sol mixture. The sol mixture is spray dried to form a plurality of precursor particles. The precursor particles are heated to form a lithium titanate composite electrode material. | 2011-09-29 |
20110236300 | PROCESS FOR PRODUCTION OF A METAL HYDRIDE - A process for production of a metal hydride compound MH | 2011-09-29 |
20110236301 | Metal cation-doped covalent organic framework derivatives for hydrogen storage and method of using the same - Disclosed are a novel hydrogen storage material with enhanced hydrogen storage capacity prepared by doping an organic framework material with light metal cations, and a method of using the same for hydrogen storage. The present inventive material has at least one phenyl group at each face of a triangular building unit, which is doped with metal cations such as alkali metal cations, alkali-earth metal cations, etc., so that the material exhibits greatly improved capacity of hydrogen absorption and desorption at room temperature and can provide hydrogen storage materials practically adapted for fuel batteries useable even at room temperature. | 2011-09-29 |
20110236302 | CATALYST, METHOD FOR PRODUCING THE CATALYST, AND METHOD FOR PRODUCING HYDROGEN USING THE CATALYST - According to one embodiment, there is provided a catalyst including a first structure including a metal oxide substrate having a pore, and a fine particle including Cu as a main component supported on an inner surface of the substrate facing the pore, and a second structure formed on the outer surface of the first structure and including Cu as a main component. The second structure is formed into a needle with a tip thereof oriented outward from the first structure. | 2011-09-29 |
20110236303 | Hydrogen-Generating Reactors And Methods - Reactors and methods that generate hydrogen from fuel, such as naturally-occurring or synthesized hydrocarbon fuel. One embodiment of the reactor comprises a CO | 2011-09-29 |
20110236304 | STRUCTURAL VARIANTS OF ANTIBODIES FOR IMPROVED THERAPEUTIC CHARACTERISTICS - The present invention provides substituted humanized, chimeric or human anti-CD20 antibodies or antigen binding fragments thereof and bispecific antibodies or fusion proteins comprising the substituted antibodies or antigen binding fragments thereof. The antibodies, fusion proteins or fragments are useful for treatment of B-cell disorders, such as B-cell malignancies and autoimmune diseases, as well as GVHD, organ transplant rejection, and hemolytic anemia and cryoglobulinemia. Amino acid substitutions, particularly substitution of an aspartate residue at Kabat position 101 of CDR3 V | 2011-09-29 |
20110236305 | METHODS FOR PROTECTING AND REGENERATING BONE MARROW USING CXCR3 AGONISTS AND ANTAGONISTS - CXCR3 agonists, including natural CXCR3 ligands, promote bone marrow regeneration, increase peripheral white blood cells, and increase survival if administered prior to treatment of a subject with chemotherapy or radiotherapy. Similar effects are obtained by administering an CXCR3 antagonists following chemotherapy radiotherapy. Compositions and methods are presented for the treatment of cancer and bone marrow diseases. | 2011-09-29 |
20110236306 | COMPOSITIONS AND METHODS FOR THE REMOVAL OF BIOFILMS - This invention provides isolated or recombinant polypeptides that are useful to vaccinate individuals suffering from chronic/recurrent biofilm disease or as a therapeutic for those with an existing infection. The individual's immune system will then naturally generate antibodies which prevent or clear these bacteria from the host by interfering with the construction and or maintenance of a functional protective biofilm. Alternatively, antibodies to the polypeptides can be administered to treat or prevent infection. Bacteria that cannot form functional biofilms are more readily cleared by the remainder of the host's immune system. | 2011-09-29 |
20110236307 | IN VIVO IMAGING METHOD - The present invention provides an in vivo imaging method that facilitates the diagnosis of Parkinson's disease (PD) at an early stage. Early diagnosis is particularly advantageous as neuroprotective treatment can be applied to healthy neural cells to delay or even prevent the onset of debilitating clinical symptoms. | 2011-09-29 |
20110236308 | Aryl Bidentate Isonitriles and Their Uses - The present invention relates generally to chelation compounds, radionuclide metal chelate compounds, i.e., complexes, and radiolabeled targeting moieties, i.e., conjugates, formed therefrom, and methods of using these compounds, complexes and conjugates for diagnostic and therapeutic purposes. This invention is more particularly related to aryl bidentate isonitrile metal complexes generated by a chemical interaction of a metal salt oxide or weak complex of the metal with aryl isonitrile bidentate ligands. | 2011-09-29 |
20110236309 | ANTAGONISTS OF LIGANDS AND USES THEREOF - The invention provides hetero-multivalent ligand binging agents (traps) for members of the TGF-β superfamily, as well as methods for making and using such constructs. In an embodiment of the invention there is provided a hetero-multivalent binding agent with affinity for a member of the TGF-β superfamily, said agent comprising the general structure (I): (-linker1) | 2011-09-29 |
20110236310 | LABELING COMPOSITION FOR INTRAOCULAR TISSUE, LABELING METHOD OF INTRAOCULAR TISSUE, AND SCREENING METHOD - The invention provides a labeling composition for an intraocular tissue of a living individual, which specifically labels the intraocular tissue without need of an invasive operation such as exposure of an ocular tissue or injection of a staining agent into the ocular tissue or a nerve tissue linking to the ocular tissue, a method of noninvasively labeling an intraocular tissue of a living individual, and a screening method using the labeling composition for the intraocular tissues. The composition contains a compound capable of labeling at least a photoreceptor cell layer of a retina, wherein the compound is a staining compound having a particular structure as a partial structure thereof. | 2011-09-29 |
20110236311 | RADIOLABELLING METHODS - The invention relates to radiodiagnostic and radiotherapeutic agents, including biologically active vectors labelled with radionuclides. It further relates to methods and reagents labelling a vector such as a peptide comprising reaction of a compound of formula (I) with a compound of formula (II): | 2011-09-29 |
20110236312 | NUCLEOSIDE ANALOGUES USEFUL AS POSITRON EMISSION TOMOGRAPHY (PET) IMAGING AGENTS - The invention provides compounds that comprise a 4′-thio nucleoside that is a derivative of 4′-thiothymidine or 4′-thio-2′-deoxyuridine comprising a positron or single photon emitting radioisotope or corresponding non-radioactive isotope attached via a triazole link to the N-3 position. Methods for preparing such compounds and uses of the compounds in medicine are also provided. | 2011-09-29 |
20110236313 | HUMAN SALTY TASTE RECEPTOR AND METHODS OF MODULATING SALTY TASTE PERCEPTION - Methods for identifying modulators of the epithelial sodium ion channel and for identifying modulators of salty taste perception are described. Also featured are isolated human salty taste receptors, artificial lipid bilayers comprising an epithelial sodium ion channels, and kits for practicing the claimed methods. | 2011-09-29 |
20110236314 | METHOD OF DETECTION AND DIAGNOSIS OF ORAL AND NASOPHARYNGEAL CANCERS - The present invention relates to cancer and in particular to oral and nasopharyngeal cancers. In particular, the present invention relates to a method of detection and diagnosis of oral squamous cell carcinoma (OSCC) and nasopharyngeal cancers by determining the expression levels of certain genes. The method comprising (a) determining in a biological sample from the patient the amount of the expression level of at least one gene selected from the group consisting of GNA-12 and IFITM3; and (b) comparing the determined expression levels of said genes in said biological sample with the level in a reference. The invention also relates to polypeptides, antibodies and nucleic acids of the invention for use in medicine and a kit for performing the invention. | 2011-09-29 |
20110236315 | Ligands for Semiconductor Nanocrystals - In this invention, polyimidazole ligands (PILs) incorporating pendant imidazole moieties for nanocrystal binding and either sulfonatebetaine, carboxybetaine, or phosphocholinebetaine moieties for water-solubilization have been developed. Greatly enhanced stability of nanocrystals (both over time and in wide pH range) was achieved by incorporating multi-dentate imidazole moieties which provide strong coordination of the ligand to the nanocrystal surface and prevent aggregation of nanocrystals. Synthesis of betaine PILs was developed by modifying the synthesis of recently developed PEG containing poly imidazole ligands (PEG PILs). These nanocrystals are compact, water soluble, and biocompatible. | 2011-09-29 |
20110236316 | PEPTIDE TARGETING IMAGING AGENTS AND METHODS OF USE THEREOF - Described herein are peptide targeting imaging agents. The peptides are covalently attached to the imaging agent and have a specific peptide sequence that enables the imaging agent to accumulate specifically in tumor tissues. Additionally, the imaging agents are readily excreted by the subject within a short period of time after administration to the subject. Methods for using the imaging agents are also described herein. | 2011-09-29 |
20110236317 | TETRAHYDROTRIAZINE COMPOUNDS FOR TREATING DISEASES ASSOCIATED WITH AMPK ACITIVITY - The invention relates to compounds of formula (I) wherein the radicals R | 2011-09-29 |
20110236318 | ANIMAL MODEL OF AN EJACULATION-LIKE REFLEX - An animal model of an ejaculation-like reflex, wherein the ejaculation-like reflex is induced by continuous infusion of saline through a catheter extending into the proximal urethra of a non-human male animal, and wherein the urethra of the animal is occluded by extending and bending the penis at the base; and a method of screening a test substance for effectiveness in prevention or treatment of male ejaculatory dysfunction using the animal model. | 2011-09-29 |
20110236319 | METHOD OF EVALUATING PLANT PROTECTION - A method is provided for evaluating a protected plant having a protection mechanism. A population of immature insects (i.e., larvae or nymphs) belonging to an insect species having a plurality of instars is first exposed to the protected plant such that the protected plant is at least contacted thereby. The insect exposure extends for a selected time period corresponding to a sublethal exposure of the insect population to the protected plant. The exposure of the insect population to the protected plant is then halted following the selected time period and insects collected. A physical characteristic of at least some collected insects is measured. The measured physical characteristics are then statistically analyzed so as to determine an efficacy of the protection mechanism of the protected plant with respect to the insect population. Associated methods are also provided. | 2011-09-29 |
20110236320 | Ultrasound Contrast Agents And Process For The Preparation Thereof - Injectable aqueous suspension of microbubbles filled with a biocompatible gas and a method of preparation thereof. At least 10% of the total volume of gas contained in the microbubbles is contained in microbubbles with a diameter of 1.5 μm or less. The microbubbles can be obtained by preparing an emulsion comprising an aqueous medium, a phospholipid and a water immiscible organic solvent. The emulsion is then freeze-dried and then reconstituted in an aqueous suspension of gas-filled microbubbles. | 2011-09-29 |
20110236321 | Aerosol Foams Comprising Clindamycin Phosphate - Described herein are emulsions and compositions for the treatment of acne vulgaris. The emulsions may be formulated as aerosol compositions. The aerosol propellant may be a hydrofluoroalkane propellant. The emulsions or compositions may comprise clindamycin phosphate and a buffer salt, and may exhibit decreased rates of clindamycin phosphate hydrolysis. Also described are methods of treating acne vulgaris, comprising the step of applying to an affected area of a subject in need thereof a therapeutically-effective amount of an inventive emulsion or aerosol composition. | 2011-09-29 |
20110236322 | ORAL PH AND BUFFERING CAPACITY MODIFIERS - Example embodiments of the present invention include various compositions that include a pH modifier composition and/or a buffering capacity modifier composition. In some examples, the pH modifier compositions include a dose of pH modifier to raise the pH in a patient's mouth from about 1 to about 2 pH levels. The compositions are then incorporated into various confections for oral ingestion or application that allow a patient to easily use the composition with the pH and/or buffering capacity modifiers. For example, compositions with the pH and/or buffering capacity modifiers can be incorporated within chewing gum, tablets, lozenges, breath strips, hard candy, oral sprays, and other confections. Another embodiment of the invention includes a testing device to test the pH and buffering capacity within a patient's mouth. | 2011-09-29 |
20110236323 | Tooth Whitening Compositions and Methods - Non-cytotoxic compositions for tooth whitening are disclosed, as are their methods of use are also provided. | 2011-09-29 |
20110236324 | PLANT EXTRACTS, COMPOSITIONS CONTAINING SAME, AND USES THEREOF - This disclosure relates to plant extracts selected from | 2011-09-29 |
20110236325 | METHODS TO TREAT OR PREVENT A SKIN CONDITION USING A NELL1 PEPTIDE - The described invention provides methods and compositions utilizing a NELL1 peptide or nucleic acid encoding a NELL1 peptide for treating or preventing a skin condition. The methods include treating or preventing manifestations of aging in human skin, repairing damage to skin, and preventing skin scarring. Methods are also provided for assaying a test peptide for NELL1 activity. | 2011-09-29 |
20110236326 | Skin Whitener - Use of a substance of formula (I) wherein —R1, R2, R3 and R4 are independently selected from the group consisting of hydrogen (—H), methyl (—CH | 2011-09-29 |
20110236327 | Continuous Moisturization Compositions - An aqueous hair moisturizing composition is provided. The composition includes a cationic component, an oil containing about 70 percent or greater unsaturated fatty acids with chain length of C | 2011-09-29 |
20110236328 | HAIR COSMETIC COMPOSITION - A hair cosmetic composition used for dyeing, bleaching, or destaining hair contains diglycerin, 1,3-butylene glycol, and polyethylene glycol having a number average molecular weight of 10,000 or more. | 2011-09-29 |
20110236329 | HAIR COSMETIC COMPOSITION - A hair cosmetic composition used for dyeing, bleaching, or destaining hair contains a fatty acid ester, a linear-chain higher fatty acid, polyethylene glycol having a number average molecular weight of 6,000 or more, an alkaline agent, and an oxidizing agent. The fatty acid ester is an ester of a fatty acid having a carbon number of 10 or less and an alcohol. | 2011-09-29 |
20110236330 | Skin Whitening - Methods for reducing pigmentation or hyperpigmentation of skin comprising applying to the skin a substance of formula (I) in the D-form, L-form or racemic form (D,L) are disclosed: | 2011-09-29 |
20110236331 | MAKE-UP COMPOSITION - A make-up composition is for the skin, is prepared by a process and used in a makeup method. The cosmetic composition is intended for making up the skin. The composition has from 75 to 98% by weight of a powder or a mixture of powders, as well as at least one cosmetically acceptable fatty phase having at least one oil. The composition additionally includes a block copolymer of at least one styrene polymer and of at least one olefin polymer, the olefin being other than styrene, or a mixture of these block copolymers. | 2011-09-29 |
20110236332 | COSMETIC METHOD USING A COMPOSITION CONTAINING SILOXANE RESINS AND POWDER DYE - The invention relates to a cosmetic method for making-up and/or caring for keratin materials, whereby a cosmetic composition is applied to the keratin materials, in particular the skin and lips, preferably the skin, said cosmetic composition comprising siloxane resins and a powder dye that has been surface treated with a hydrophobic agent. In particular, the invention relates to compositions used to care for or make-up the aforementioned keratin materials. | 2011-09-29 |
20110236333 | Non-lonic surfactant solubilized high catechin content emulsion - The present invention solves the problem that skin or coat treatment products which use catechin extract in a “cat-ionic” or “an-ionic” base have tended to be unstable. The problem addressed is the precipitation and color change (darkening) in just a few hours/days where products would not be commercially viable due to extremely short shelf life. The Non-Ionic Surfactant Solubilized High Catechin Content Emulsion invention achieves an efficacious level of catechins (in ranges up to and over 2% by weight) as a proper emulsification method for the high catechin content in a skin, scalp, or coat treatment that does not separate or darken and has a much longer shelf-life. | 2011-09-29 |
20110236334 | PERSONAL CARE COMPOSITIONS FOR COLORING HAIR - Described are hair colorant compositions comprising an aqueous dispersion comprising an ethylene acrylic acid copolymer, and optionally a metallocene catalyzed polyolefin. an aqueous dispersion comprising a metallocene catalyzed polyolefin and an ethylene acrylic acid copolymer, and methods of reducing hair damage from hair colorants, comprising including an aqueous dispersion comprising a metallocene catalyzed polyolefin and an ethylene acrylic acid copolymer in the hair colorant. | 2011-09-29 |
20110236335 | PERHYDROLASE PROVIDING IMPROVED SPECIFIC ACTIVITY - An acetyl xylan esterase variant having perhydrolytic activity is provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. More specifically, a | 2011-09-29 |
20110236336 | PERHYDROLASE PROVIDING IMPROVED SPECIFIC ACTIVITY - An acetyl xylan esterase variant having perhydrolytic activity is provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. More specifically, a | 2011-09-29 |
20110236337 | PERHYDROLASE PROVIDING IMPROVED SPECIFIC ACTIVITY - An acetyl xylan esterase variant having perhydrolytic activity is provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. More specifically, a | 2011-09-29 |
20110236338 | PERHYDROLASE PROVIDING IMPROVED SPECIFIC ACTIVITY - An acetyl xylan esterase variant having perhydrolytic activity is provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. More specifically, a | 2011-09-29 |
20110236339 | PERHYDROLASE PROVIDING IMPROVED SPECIFIC ACTIVITY - An acetyl xylan esterase variant having perhydrolytic activity is provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. More specifically, a | 2011-09-29 |
20110236340 | CROSSLINKED CATION EXCHANGE POLYMERS, COMPOSITIONS AND USE IN TREATING HYPERKALEMIA - The present invention is directed to crosslinked cation exchange polymers comprising a fluoro group and an acid group, pharmaceutical compositions of these polymers, compositions of a linear polyol and a salt of such polymer. Crosslinked cation exchange polymers having beneficial physical properties, including combinations of particle size, particle shape, particle size distribution, viscosity, yield stress, compressibility, surface morphology, and/or swelling ratio are also described. These polymers and compositions are useful to bind potassium in the gastrointestinal tract. | 2011-09-29 |
20110236341 | COSMETIC METHOD USING A COMPOSITION CONTAINING SILOXANE RESINS AND A NON-VOLATILE OIL - The invention relates to a cosmetic method for making-up and/or caring for keratin materials, in particular the skin, whereby a cosmetic composition is applied to the keratin materials, said cosmetic composition taking the form of an emulsion and comprising siloxane resins and a non-volatile hydrocarbon oil. In particular, the invention relates to compositions used to care for or make-up the aforementioned keratin materials. | 2011-09-29 |
20110236342 | COSMETIC METHOD USING A COMPOSITION CONTAINING SILOXANE RESINS AND SPECIFIC NON-IONIC SURFACTANT - The invention relates to a cosmetic method for making-up and/or caring for keratin materials, in particular the skin, whereby a cosmetic composition is applied to the keratin materials, said cosmetic composition taking the form of an emulsion and comprising siloxane resins and a specific nonionic silicone surfactant. In particular, the invention relates to compositions used to care for or make-up the aforementioned keratin materials. | 2011-09-29 |
20110236343 | Antimicrobial polysiloxane materials containing metal species - Polysiloxane-based materials, which include metal species, are provided. The polysiloxane-based compositions and materials generally include (i) amino-functional polysiloxane material and (ii) a plurality of metal species distributed within the polymeric material. Polymer based compositions in which the amino-functional polysiloxane material includes quaternary ammonium groups, e.g., tetraalkyl ammonium groups, are examples of suitable materials which may be used to form the present compositions. The metal species, which may be in an oxidized and/or neutral state, may be bonded, coordinated, chelated, suspended, and/or dispersed within the polymeric material. | 2011-09-29 |
20110236344 | Synthetic mimics of mammalian cell surface receptors: method and compositions - The present invention relates to new synthetic receptors. More particularly, the present invention relates to the use of the synthetic receptors for delivering a protein, peptide, drug, prodrug, lipid, nucleic acid, carbohydrate or small molecule into a target cell via receptor-mediated endocytosis. According to the invention, novel synthetic mimics of cell surface receptors have been designed and methods for use of the same are disclosed. | 2011-09-29 |
20110236345 | COMPOSITION AND METHODS FOR ELICITING AN IMMUNE RESPONSE - The present invention relates to compositions, methods, and kits for eliciting an immune response, in particular for eliciting an immune response to at least one antigen expressed by a cancer cell, in particular for treating and preventing cancer. | 2011-09-29 |
20110236346 | Compositions and Methods for Treatment of Radiation Exposure - The present invention relates to an immunostimulant and to the use of an immunostimulant in the form of a cross-linked muramyl dipeptide microparticle in the treatment of radiation exposure, radiation poisoning, and mitigating the toxic effects of radiotherapy. | 2011-09-29 |
20110236347 | Monoclonal Anti-Claudin 1 Antibodies for the Inhibition of Hepatitis C Virus Infection - The present invention provides monoclonal antibodies that specifically bind to the extracellular domain of human Claudin-1 on the cell surface, thereby inhibiting HCV entry into susceptible cells and preventing HCV infection of these cells; and hybridoma cell lines which produce such monoclonal antibodies. Also provided are reagents that comprise such antibodies, and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing HCV infection by administration of an inventive monoclonal antibody, or a pharmaceutical composition thereof are also described. | 2011-09-29 |
20110236348 | MODULATORS OF TOLL-LIKE RECEPTOR 7 - The present invention includes therapeutic methods that include the administration of a compound of Formula I or II: | 2011-09-29 |
20110236349 | Use of Epidermal Growth Factor Inhibitors in the Treatment of Viral Infection - The present invention provides methods of treating a viral infection in an individual. The methods generally involve administering to an individual an effective amount of an epidermal growth factor receptor (EGF-R) inhibitor. | 2011-09-29 |
20110236350 | ESTROGEN RECEPTOR LIGAND TREATMENT FOR NEURODEGENERATIVE DISEASES - The present invention relates to treatment of neurological diseases such as multiple sclerosis (MS) and Alzheimer's disease, using an estrogen receptor beta (ERβ) ligand in combination with a standard, anti-inflammatory agent. | 2011-09-29 |
20110236351 | Therapeutic Regimen Comprising PEG-Interferon, Ribavirin and VX-950 for the Treatment of Hepatitis - The present invention relates to antiviral therapies and compositions for treating or preventing Hepatitis C infections in patients and relates to other methods disclosed herein. The invention also relates to kits and pharmaceutical packs comprising compositions and dosage forms. | 2011-09-29 |
20110236352 | PEGylation by the Dock and Lock (DNL) Technique - The present invention concerns methods and compositions for forming PEGylated complexes of defined stoichiometry and structure. In preferred embodiments, the PEGylated complex is formed using dock-and-lock technology, by attaching a target agent to a DDD sequence and attaching a PEG moiety to an AD sequence and allowing the DDD sequence to bind to the AD sequence in a 2:1 stoichiometry, to form PEGylated complexes with two target agents and one PEG moiety. In alternative embodiments, the target agent may be attached to the AD sequence and the PEG to the DDD sequence to form PEGylated complexes with two PEG moieties and one target agent. In more preferred embodiments, the target agent may comprise any peptide or protein of physiologic or therapeutic activity. The PEGylated complexes exhibit a significantly slower rate of clearance when injected into a subject and are of use for treatment of a wide variety of diseases. | 2011-09-29 |
20110236353 | ADENO-ASSOCIATED VIRUS (AAV) CLADES, SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREFOR - Sequences of novel adeno-associated virus capsids and vectors and host cells containing these sequences are provided. Also described are methods of using such host cells and vectors in production of rAAV particles. AAV-mediated delivery of therapeutic and immunogenic genes using the vectors of the invention is also provided. | 2011-09-29 |
20110236354 | Symbiotic bacterial oncolysis-a beacon-based method for enhanced destruction of solid tumors-including both the tumor core and rim - Symbiotic bacterial oncolysis is a method to directly lyse and/or otherwise destroy the tumor core and rim of solid tumors using two (or more) phases of treatment. The first phase localizes with specificity for features of tumor microenvironment. The second (and/or subsequent) phase(s)—otherwise known as the SYMBIOT—localizes with specificity for features—designed, selected or inherent—of an earlier treatment phase (typically the phase 1). This earlier phase (typically phase 1) acts as a BEACON to help improve the specificity and/or localization of the subsequent—SYMBIOT—phases of treatment. Overall this should lead to improved solid tumor destruction relative to current art. | 2011-09-29 |
20110236355 | DIFFERENTIATION OF STEM CELLS INTO DOPAMINERGIC CELLS - Methods for differentiating stem cells are disclosed herein. These methods can be used to generate neurons, including, but not limited to, dopaminergic neurons. The disclosed methods include culturing stem cells in the absence of fibroblast growth factor-2 to generate embryoid bodies and culturing the embryoid bodies in the presence of an effective amount of at least one of stromal cell-derived factor 1, pleiotrophin, insulin-like growth factor 2, and ephrin B1 on an extracellular matrix for a period of time sufficient to produce dopaminergic neuronal cells. The differentiated cells can be used to study pharmaceutical agents that affect dopaminergic neurons and can be used in the treatment of neurodegenerative disorders such as Parkinson's disease. | 2011-09-29 |
20110236356 | METHODS OF ISOLATING AND USING STEM CELLS - Methods of isolating and using stem cells from neural crest, e.g. periodontal ligament, isolated stem cell and therapeutic cell cultures, and therapeutic applications for a variety of conditions. The cells and cell cultures are especially useful for autologous administration. | 2011-09-29 |
20110236357 | BONE MARROW-DERIVED MESENCHYMAL STEM CELLS AS A SOURCE OF NEURAL PROGENITORS - Methods are provided for treating and/or reducing the severity of multiple sclerosis in a human, by administering autologous mesenchymal stem cell-derived neural precursors. Also described is an in vitro method for differentiating mesenchymal stem-cell derived neural precursor oligodengroglial and neuronal cell types. | 2011-09-29 |
20110236358 | COMPOSITION COMPRISING ISOFLAVONES - A composition comprising at least one isoflavone, phloridzin and one or more probiotics. A composition as described herein is also provided for internal use as a natural alternative to hormone replacement therapy and for treating disorders such as menopause and correlated symptoms, alcoholism, stress, insomnia, obesity and cellulite. | 2011-09-29 |
20110236359 | Antimicrobial Activity of Bacteriocin-Producing Lactic Acid Bacteria - The present invention relates to novel bacteriocin-producing lactic acid bacteria strains | 2011-09-29 |
20110236360 | LACTIC ACID BACTERIUM HAVING HIGH OXALIC ACID DECOMPOSITION ABILITY - The present invention provides lactic acid bacteria having oxalic acid-degrading activity several times higher than those of conventionally known lactic acid bacteria having an oxalic acid-degrading activity, and uses thereof. Lactic acid bacteria capable of degrading a large amount of oxalic acid were screened from 132 strains of | 2011-09-29 |
20110236361 | EFFECTIVE CONTROL OF VIRAL PLANT DISEASE WITH STRAINS OF PSEUDOMONAS OLEOVORANS - A strain of | 2011-09-29 |
20110236362 | NKT CELL-DERIVED iPS CELLS AND NKT CELLS DERIVED THEREFROM - Provided are an iPS cell derived from a somatic cell such as an NKT cell, having the α-chain region of the T cell antigen receptor gene rearranged to uniform Vα-Jα in an NKT cell receptor-specific way, NKT cells differentiated from the iPS cell, a method of creating the same, and an immune cell therapy agent prepared using cells differentiated from the iPS cell. Also provided are an iPS cell having TCRα rearranged to NKT-TCR (NKT-iPS cell), obtained by contacting a somatic cell, such as an NKT cell, having the α-chain region of the T cell antigen receptor gene rearranged to uniform Vα-Jα in an NKT cell receptor-specific way, with nuclear reprogramming factors, isolated NKT cells obtained by differentiating the iPS cell ex vivo (iPS-NKT cell), a method of generating CD4/CD8-double positive NKT cells (DP-NKT cells) and mature NKT cells from NKT-iPS cells by altering the combination of feeder cells and/or cytokines, a method of expanding the iPS-NKT cells, and an NKT cell cytotherapy agent comprising NKT cells activated with α-galactosyl ceramide (α-GalCer), or iPS-NKT cells, and α-GalCer in combination. | 2011-09-29 |
20110236363 | SYSTEM AND METHOD FOR PRODUCING T CELLS - Disclosed herein is a system and method for producing T cells from stem cell populations. Specifically exemplified herein is a culture system and method that produces CD4 cells and/or T cell subtypes from a CD4 lineage using a sample of hematopoietic stem cells. Adult hematopoietic precursor/stem cells (HPC) are progenitors to all lineages of immune cells. There has been limited success in generating functional CD4 T cells with this convenient culture system. Also disclosed herein is a novel stromal cell line expressing DL1, interleukin-7 (IL-7), and FMS-like tyrosine kinase 3 ligand (Flt3-L). This improved culture system can greatly facilitate the study of late T cell development and enables immunotherapeutic applications. | 2011-09-29 |
20110236364 | Compositions containing non-polar compounds - Provided are compositions and methods for clear and stable beverages that contain additives such as essential fatty acids, including omega-3 fatty acids, omega-6 fatty acids, conjugated fatty acids, and other fatty acids; phytochemicals, including phytosterols; other oils; and coenzymes, including Coenzyme Q10, and other oil-based additives. | 2011-09-29 |
20110236365 | METHOD FOR PROTECTING AND TREATING AT LEAST ONE MUSCARINIC RECEPTOR FROM DYSFUNCTION RESULTING FROM FREE RADICAL DAMAGE - Methods and compositions for enhancing cellular function through protection of a tissue components such receptors, proteins, lipids, nucleic acids, carbohydrates, hormones, vitamins, and cofactors, by administering pyrophosphate analogs or related compounds. | 2011-09-29 |
20110236366 | PRODUCTION AND USES OF TYPE I RIBOSOME INACTIVATING PROTEINS - Described herein are methods to express and purify recombinant type 1 ribosome inactivating proteins. Included are methods for using recombinant cucurmosin as a therapeutic to treat cancer and infectious diseases. | 2011-09-29 |
20110236367 | RAT CATHESPIN DIPEPTIDYL PEPTIDASE I (DPPI): CRYSTAL STRUCTURE AND ITS USES - The present invention relates to structural studies of dipeptidyl peptidase I (DPPI) proteins, modified dipeptidyl peptidase I (DPPI) proteins and DPPI co-complexes. Included in the present invention is a crystal of a dipeptidyl peptidase I (DPPI) and corresponding structural information obtained by X-ray crystallography from rat and human DPPI. In addition, this invention relates to methods for using structure co-ordinates of DDPI, mutants hereof and co-complexes, to design compounds that bind to the active site or accessory binding sites of DPPI and to design improved inhibitors of DPPI or homologues of the enzyme. | 2011-09-29 |
20110236368 | ORAL MEDICATION FOR THE TREATMENT OF HEMORRHOIDS AND METHOD OF USE - A natural supplement in the form of an orally ingested tablet for treatment of hemorrhoids. Bromelain and Psyllium (e.g., Psyllium husk powder) are the primary active ingredients in the natural supplement tablet. Optionally, Witch Hazel, in the form of Witch Hazel leaf, for example, may be added to the composition. Secondary ingredients include Dicalcium Phosphate, Cellulose, Croscarmellose Sodium, Stearic Acid and Silicon Dioxide. Based on case studies the natural supplement outperforms over-the-counter and prescribed hemorrhoid medications. | 2011-09-29 |
20110236369 | Dosage Forms That Facilitate Rapid Activation of Zymogen - The therapeutic efficacy of zymogen proteins for oral administration is improved by including in the formulation one or more excipients that optimize pH and other reaction conditions for rapid activation of the zymogen shortly after ingestion. | 2011-09-29 |
20110236370 | Genetic Alterations on Chromosomes 21q, 6q and 15q and Methods of Use Thereof for the Diagnosis and Treatment of Type I Diabetes - Compositions and methods for the detection and treatment of T1D are provided. | 2011-09-29 |
20110236371 | Compositions And Methods For The Treatment Of Neurologic And Psychiatric Conditions - The invention provides pharmaceutical compositions and methods of use thereof for preventing or ameliorating disorders of the nervous system. More specifically, the invention provides pharmaceutical compositions, including phosphopeptides, that when administered disrupt TrkB-mediated activation of PLCγ1 phosphorylation. The invention further provides method of treatment comprising administering inhibitors of TrkB-mediated activation of PLCγ1 phosphorylation alone or in combination with other pharmaceutical compositions to prevent or ameliorate nervous system disorders such as epilepsy, stroke, anxiety, migraine, and pain. | 2011-09-29 |
20110236372 | Display Library for Antibody Selection - Synthetic antibody display library containing human germline antibody molecules with variation in VH CDR3 and VL CDR3 and at position 52 of VH CDR2, for screening and selection of antibody molecules specific for antigens of interest. | 2011-09-29 |
20110236373 | Method of detecting antibodies and antibody-hiv virion complexes - The present invention relates, in general, to HIV and, in particular to a method of detecting anti-HIV antibodies and antibody-HIV virion complexes. | 2011-09-29 |
20110236374 | GENETICALLY RECOMBINANT ANTIBODY COMPOSITION CAPABLE OF BINDING SPECIFICALLY TO GANGLIOSIDE GM2 - The present invention relates to a genetically recombinant antibody composition which specifically binds to ganglioside GM2, which has higher complement-dependent cytotoxic activity than a human IgG1 antibody and a human IgG3 antibody, wherein a polypeptide comprising a CH2 domain in the Fc region of a human IgG1 antibody is replaced by a polypeptide comprising an amino acid sequence which corresponds to the same position of a human IgG3 antibody indicated by the EU index as in Kabat, et al.; a DNA encoding the antibody molecule or a heavy chain constant region of the antibody molecule contained in the recombinant antibody composition; a transformant obtainable by introducing the recombinant vector into a host cell; a process for producing the recombinant antibody composition using the transformant; and a medicament comprising the recombinant antibody composition as an active ingredient. | 2011-09-29 |
20110236375 | ANTIBODY VARIANTS WITH ENHANCED COMPLEMENT ACTIVITY - The present invention relates to novel Fc variants that comprise at least one novel amino acid residue which may provide for enhanced effector function. More specifically, this invention provides Fc variants that have modified binding affinity to one or more Fc receptor or ligand (e.g., Fc gamma R, C1q). Additionally, the Fc variants have altered complement dependent cytotoxicity (CDC) activity and/or antibody-dependent cell-mediated cytotoxicity (ADCC). The invention further provides methods and protocols for the application of said Fc variants, particularly for therapeutic purposes. | 2011-09-29 |
20110236376 | NON-NEUTRALIZING IMMUNITY TO INFLUENZA TO PREVENT SECONDARY BACTERIAL PNEUMONIA - The prevention and treatment of secondary bacterial pneumonia is described, by using passive immunization with antibodies (e.g. polyclonal, monoclonal, etc.) to one or more conserved influenza proteins. Both antibodies and fragments thereof are contemplated, raised against conserved proteins such as nucleoproteins. | 2011-09-29 |